Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Demeetra AgBio

Main focus: Therapeutic cannabis

Company stage: IND filing

Diseases: Undisclosed

Genome editing tool: Cas-CLOVER

Funding stage: Private

Location: Lexington, KY, USA

Website: https://demeetra.com/

Partners: Poseida Therapeutics, Sanofi

Demeetra Agbio is a privately held agricultural and therapeutic gene-editing company. Based in Kentrucky, US, the company utilises its proprietary Cas-CLOVER platform to genetically modify plants for pharmaceutical use. The Cas-CLOVER system uses two guide RNAs (gRNAs) rather than the conventional single gRNA used in CRISPR-Cas9 editing. Demeetra Agbio's components are licensed to several companies including Sanofi and Poseida Therapeutics.

Your Latest CMN News

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Gene-Editing Clinical Trial Updates - What's...

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

Company: Demeetra AgBio

Search CRISPR Medicine